Cinzia Perrino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3484115/publications.pdf

Version: 2024-02-01

94 papers 3,812 citations

35 h-index 59 g-index

95 all docs 95 docs citations

95 times ranked 6592 citing authors

#	Article	IF	CITATIONS
1	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2022, 118, 3016-3051.	1.8	30
2	Mitochondrial a Kinase Anchor Proteins in Cardiovascular Health and Disease: A Review Article on Behalf of the Working Group on Cellular and Molecular Biology of the Heart of the Italian Society of Cardiology. International Journal of Molecular Sciences, 2022, 23, 7691.	1.8	1
3	The role of mitochondrial dynamics in cardiovascular diseases. British Journal of Pharmacology, 2021, 178, 2060-2076.	2.7	118
4	Improving translational research in sex-specific effects of comorbidities and risk factors in ischaemic heart disease and cardioprotection: position paper and recommendations of the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2021, 117, 367-385.	1.8	53
5	Transverse aortic constriction induces gut barrier alterations, microbiota remodeling and systemic inflammation. Scientific Reports, 2021, 11, 7404.	1.6	13
6	Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal, 2021, 42, 2630-2642.	1.0	69
7	COVID-19-related cardiac complications from clinical evidences to basic mechanisms: opinion paper of the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2021, 117, 2148-2160.	1.8	26
8	Circadian rhythms in ischaemic heart disease: key aspects for preclinical and translational research: position paper of the ESC working group on cellular biology of the heart. Cardiovascular Research, 2021, , .	1.8	10
9	Aortic thrombosis: the forgotten source of ischemic stroke. A case report and systematic review of the literature. Monaldi Archives for Chest Disease, 2021, , .	0.3	O
10	Ageing, sex, and cardioprotection. British Journal of Pharmacology, 2020, 177, 5270-5286.	2.7	46
11	Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome. Journal of Cardiovascular Medicine, 2020, 21, 660-666.	0.6	10
12	Cardiomyocyte ageing and cardioprotection: consensus document from the ESC working groups cell biology of the heart and myocardial function. Cardiovascular Research, 2020, 116, 1835-1849.	1.8	34
13	Novel Basic Science Insights to Improve the Management of Heart Failure: Review of the Working Group on Cellular and Molecular Biology of the Heart of the Italian Society of Cardiology. International Journal of Molecular Sciences, 2020, 21, 1192.	1.8	8
14	Diastolic dysfunction in severe aortic stenosis: Old but still gold. Catheterization and Cardiovascular Interventions, 2020, 95, 1032-1033.	0.7	O
15	Diagnostics and therapeutic implications of gut microbiota alterations in cardiometabolic diseases. Trends in Cardiovascular Medicine, 2019, 29, 141-147.	2.3	36
16	Inflammation in aortic stenosis: Shaping the biomarkers network. International Journal of Cardiology, 2019, 274, 279-280.	0.8	1
17	Epac1 inhibition as a novel cardioprotective strategy: lights and shadows on GRK5 canonical and non-canonical functions. Cardiovascular Research, 2019, 115, 1684-1686.	1.8	2
18	Effects of Carvedilol Versus Metoprolol on Platelet Aggregation in Patients With Acute Coronary Syndrome: The PLATE-BLOCK Study. American Journal of Cardiology, 2018, 122, 6-11.	0.7	13

#	Article	IF	CITATIONS
19	<i>Akap1</i> Regulates Vascular Function and Endothelial Cells Behavior. Hypertension, 2018, 71, 507-517.	1.3	33
20	Perivascular fibrosis and the microvasculature of the heart. Still hidden secrets of pathophysiology?. Vascular Pharmacology, 2018, 107, 78-83.	1.0	23
21	Epigenetic modulation of vascular diseases: Assessing the evidence and exploring the opportunities. Vascular Pharmacology, 2018, 107, 43-52.	1.0	10
22	Loss of Akap1 Exacerbates Pressure Overload-Induced Cardiac Hypertrophy and Heart Failure. Frontiers in Physiology, 2018, 9, 558.	1.3	28
23	Akap-mediated signalling: the importance of being in the right place at the right time. Cardiovascular Research, 2017, 113, 115-117.	1.8	2
24	Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2017, 113, 725-736.	1.8	114
25	Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2017, 113, 564-585.	1.8	278
26	ESC Joint Working Groups on Cardiovascular Surgery and the Cellular Biology of the Heart Position Paper: Peri-operative myocardial injury and infarction in patients undergoing coronary artery bypass graft surgery. European Heart Journal, 2017, 38, 2392-2411.	1.0	118
27	Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. European Heart Journal, 2017, 38, 2948-2956.	1.0	383
28	New-onset atrial fibrillation and increased mortality after transcatheter aortic valve implantation: A causal or spurious association?. International Journal of Cardiology, 2016, 203, 264-266.	0.8	24
29	Cardiovascular effects of histone deacetylase inhibitors epigenetic therapies: Systematic review of 62 studies and new hypotheses for future research. International Journal of Cardiology, 2016, 219, 396-403.	0.8	34
30	Tako-tsubo syndrome and myocarditis: Two sides of the same coin or same side for two different coins?. International Journal of Cardiology, 2016, 203, 40-42.	0.8	3
31	Akap1 Deficiency Promotes Mitochondrial Aberrations and Exacerbates Cardiac Injury Following Permanent Coronary Ligation via Enhanced Mitophagy and Apoptosis. PLoS ONE, 2016, 11, e0154076.	1.1	39
32	A meta-analysis of the impact of pre-existing and new-onset atrial fibrillation on clinical outcomes in patients undergoing transcatheter aortic valve implantation. EuroIntervention, 2016, 12, e1047-e1056.	1.4	80
33	Aortic and Mitral Calcification Is Marker of Significant Carotid and Limb Atherosclerosis in Patients with First Acute Coronary Syndrome. Echocardiography, 2015, 32, 1771-1777.	0.3	4
34	Novel Molecular Approaches in Heart Failure: Seven Trans-Membrane Receptors Signaling in the Heart and Circulating Blood Leukocytes. Frontiers in Cardiovascular Medicine, 2015, 2, 13.	1.1	6
35	New Cerebral Lesions at Magnetic Resonance Imaging after Carotid Artery Stenting Versus Endarterectomy: An Updated Meta-Analysis. PLoS ONE, 2015, 10, e0129209.	1.1	32
36	The Murine Model of Mucopolysaccharidosis IIIB Develops Cardiopathies over Time Leading to Heart Failure. PLoS ONE, 2015, 10, e0131662.	1.1	24

#	Article	IF	CITATIONS
37	Moderate and Severe Preoperative Chronic Kidney Disease Worsen Clinical Outcomes After Transcatheter Aortic Valve Implantation. Circulation: Cardiovascular Interventions, 2015, 8, e002220.	1.4	73
38	Impact of postoperative acute kidney injury on clinical outcomes after transcatheter aortic valve implantation: A metaâ€analysis of 5,971 patients. Catheterization and Cardiovascular Interventions, 2015, 86, 518-527.	0.7	75
39	Impact of moderate preoperative chronic kidney disease on mortality after transcatheter aortic valve implantation. International Journal of Cardiology, 2015, 189, 77-78.	0.8	5
40	Embolic protection devices during carotid artery stenting: Is there a difference between proximal occlusion and distal filter?. International Journal of Cardiology, 2015, 187, 592-593.	0.8	3
41	Dermcidin: a skeletal muscle myokine modulating cardiomyocyte survival and infarct size after coronary artery ligation. Cardiovascular Research, 2015, 107, 431-441.	1.8	27
42	Prognostic role of transthoracic echocardiography in patients affected by heart failure and reduced ejection fraction. Heart Failure Reviews, 2015, 20, 305-316.	1.7	22
43	Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management. Current Vascular Pharmacology, 2014, 12, 106-116.	0.8	26
44	Epigenetic Switch at Atp2a2 and Myh7 Gene Promoters in Pressure Overload-Induced Heart Failure. PLoS ONE, 2014, 9, e106024.	1.1	42
45	Physical activity in the prevention of peripheral artery disease in the elderly. Frontiers in Physiology, 2014, 5, 12.	1.3	15
46	tURn the Lights on: Mitochondrial Transportâ€RNAs and Cardiovascular Disease. Journal of the American Heart Association, 2014, 3, e000757.	1.6	0
47	Cerebral Embolic Lesions Detected With Diffusion-Weighted Magnetic Resonance Imaging Following Carotid Artery Stenting. JACC: Cardiovascular Interventions, 2014, 7, 1177-1183.	1.1	80
48	Increased mortality after transcatheter aortic valve implantation (TAVI) in patients with severe aortic stenosis and low ejection fraction: A meta-analysis of 6898 patients. International Journal of Cardiology, 2014, 176, 32-39.	0.8	54
49	Meta-Analysis of Mortality Outcomes and Mitral Regurgitation Evolution in 4,839 Patients Having Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis. American Journal of Cardiology, 2014, 114, 875-882.	0.7	60
50	Non-invasive vulnerable plaque imaging: how do we know that treatment works?. European Heart Journal Cardiovascular Imaging, 2014, 15, 1194-1202.	0.5	12
51	Epigenetic modifications induced by Helicobacter pylori infection through a direct microbe–gastric epithelial cells cross-talk. Medical Microbiology and Immunology, 2013, 202, 327-337.	2.6	19
52	Transradial approach for the endovascular treatment of type I endoleak after aortic aneurysm repair: a case report. BMC Surgery, 2013, 13, S47.	0.6	8
53	Effects of successful percutaneous lower extremity revascularization on cardiovascular outcome in patients with peripheral arterial disease. International Journal of Cardiology, 2013, 167, 2566-2571.	0.8	27
54	Genetic Deletion of Uncoupling Protein 3 Exaggerates Apoptotic Cell Death in the Ischemic Heart Leading to Heart Failure. Journal of the American Heart Association, 2013, 2, e000086.	1.6	50

#	Article	IF	Citations
55	Unexpected preserved brain perfusion imaging despite severe and diffuse atherosclerosis of supra-aortic trunks: case report - online article. Cardiovascular Journal of Africa, 2013, 24, e12-e14.	0.2	4
56	Modulating G Protein-Coupled Receptors to Effect Reverse Cardiac Remodeling., 2013, , 159-177.		0
57	Femoral Plaque Echogenicity and Cardiovascular Risk in Claudicants. JACC: Cardiovascular Imaging, 2012, 5, 348-357.	2.3	24
58	Use of statins in lower extremity artery disease: a review. BMC Surgery, 2012, 12, S15.	0.6	17
59	Abdominal aortic aneurysm in patients affected by intermittent claudication: prevalence and clinical predictors. BMC Surgery, 2012, 12, S17.	0.6	28
60	Endovascular treatment of lower extremity arteries is associated with an improved outcome in diabetic patients affected by intermittent claudication. BMC Surgery, 2012, 12, S19.	0.6	11
61	Ankle/brachial index to everyone. BMC Surgery, 2012, 12, S18.	0.6	10
62	The role of atherectomy in the treatment of lower extremity peripheral artery disease. BMC Surgery, 2012, 12, S13.	0.6	40
63	Statins and the elderly: recent evidence and current indications. Aging Clinical and Experimental Research, 2012, 24, 47-55.	1.4	5
64	Total occlusion of the abdominal aorta in a patient with renal failure and refractory hypertension: a case report. Monaldi Archives for Chest Disease, 2011, 76, 43-6.	0.3	7
65	Endovascular treatment of carotid artery stenosis: evidences from randomized controlled trials and actual indications. Monaldi Archives for Chest Disease, 2011, 76, 183-91.	0.3	2
66	EGFR trans-activation by urotensin II receptor is mediated by \hat{I}^2 -arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy. Basic Research in Cardiology, 2011, 106, 577-589.	2.5	68
67	Distinct Effects of Leukocyte and Cardiac Phosphoinositide 3-Kinase γ Activity in Pressure Overload–Induced Cardiac Failure. Circulation, 2011, 123, 391-399.	1.6	65
68	Placental Growth Factor Regulates Cardiac Inflammation Through the Tissue Inhibitor of Metalloproteinases-3/Tumor Necrosis Factor-α–Converting Enzyme Axis. Circulation, 2011, 124, 1337-1350.	1.6	57
69	Cardiovascular effects of treadmill exercise in physiological and pathological preclinical settings. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H1983-H1989.	1.5	31
70	(Zebra) fishing for relevant genes in heart regeneration. Journal of Cardiovascular Medicine, 2010, 11, 631-632.	0.6	2
71	AngioJet $\hat{A}^{\text{@}}$ rheolytic thrombectomy for acute superficial femoral artery stent or femoropopliteal by-pass thrombosis. Monaldi Archives for Chest Disease, 2010, 74, 76-81.	0.3	9
72	Induction of Mitogen-Activated Protein Kinases Is Proportional to the Amount of Pressure Overload. Hypertension, 2010, 55, 137-143.	1.3	24

#	Article	IF	CITATIONS
73	AKAP121 downregulation impairs protective cAMP signals, promotes mitochondrial dysfunction, and increases oxidative stress. Cardiovascular Research, 2010, 88, 101-110.	1.8	59
74	Rotational atherectomy for the treatment of isolated femoral artery traumatic lesion: a case report. Monaldi Archives for Chest Disease, 2009, 72, .	0.3	0
75	Endovascular repair for isolated iliac artery aneurysms: case report and review of the current literature. Journal of Cardiovascular Medicine, 2009, 10, 861-865.	0.6	4
76	Increased myocardial contractility and enhanced exercise function in transgenic mice overexpressing either adenylyl cyclase 5 or 8. Basic Research in Cardiology, 2008, 103, 22-30.	2.5	26
77	Differences in Echocardiographic Assessment with Standard Doppler and Tissue Doppler Imaging of Left Ventricular Filling Pressure in Idiopathic and Ischemic Dilated Cardiomyopathy. Echocardiography, 2008, 25, 683-691.	0.3	2
78	Dynamic Regulation of Phosphoinositide 3-Kinase- \hat{l}^3 Activity and \hat{l}^2 -Adrenergic Receptor Trafficking in End-Stage Human Heart Failure. Circulation, 2007, 116, 2571-2579.	1.6	54
79	Reversal of cardiac remodeling by modulation of adrenergic receptors: a new frontier in heart failure. Current Opinion in Cardiology, 2007, 22, 443-449.	0.8	35
80	A kinase anchor protein 121 regulates mitochondrial function and survival in cardiac and smooth muscle cells. Journal of Molecular and Cellular Cardiology, 2007, 42, S81-S82.	0.9	0
81	JNK1 is required to preserve cardiac function in the early response to pressure overload. Biochemical and Biophysical Research Communications, 2006, 343, 1060-1066.	1.0	60
82	Competitive displacement of phosphoinositide 3-kinase from \hat{l}^2 -adrenergic receptor kinase-1 improves postinfarction adverse myocardial remodeling. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H1754-H1760.	1.5	29
83	Targeted inhibition of phosphoinositide 3-kinase activity as a novel strategy to normalize \hat{l}^2 -adrenergic receptor function in heart failure. Vascular Pharmacology, 2006, 45, 77-85.	1.0	16
84	GATA4 and the Two Sides of Gene Expression Reprogramming. Circulation Research, 2006, 98, 715-716.	2.0	34
85	Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. Journal of Clinical Investigation, 2006, 116, 1547-1560.	3.9	220
86	Restoration of \hat{l}^2 -Adrenergic Receptor Signaling and Contractile Function in Heart Failure by Disruption of the \hat{l}^2 ARK1/Phosphoinositide 3-Kinase Complex. Circulation, 2005, 111, 2579-2587.	1.6	72
87	Targeted Inhibition of β-Adrenergic Receptor Kinase-1–Associated Phosphoinositide-3 Kinase Activity Preserves β-Adrenergic Receptor Signaling and Prolongs Survival in Heart Failure Induced by Calsequestrin Overexpression. Journal of the American College of Cardiology, 2005, 45, 1862-1870.	1.2	48
88	Network integration of the adrenergic system in cardiac hypertrophy. Cardiovascular Research, 2004, 63, 391-402.	1.8	81
89	Transient and reversible deoxyribonucleic acid damage in human left ventricle under controlled ischemia and reperfusion. Journal of the American College of Cardiology, 2004, 43, 1992-1999.	1.2	27
90	Role of Phosphoinositide 3-Kinase in Cardiac Function and Heart Failure. Trends in Cardiovascular Medicine, 2003, 13, 206-212.	2.3	41

#	Article	IF	CITATIONS
91	Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor Simvastatin Prevents Cardiac Hypertrophy Induced by Pressure Overload and Inhibits p21rasActivation. Circulation, 2002, 106, 2118-2124.	1.6	105
92	Membrane-Bound Protein Kinase A Inhibits Smooth Muscle Cell Proliferation In Vitro and In Vivo by Amplifying cAMP–Protein Kinase A Signals. Circulation Research, 2001, 88, 319-324.	2.0	45
93	Effects of Balloon Injury on Neointimal Hyperplasia in Streptozotocin-Induced Diabetes and in Hyperinsulinemic Nondiabetic Pancreatic Islet–Transplanted Rats. Circulation, 2001, 103, 2980-2986.	1.6	104
94	A new rat model of small vessel stenting. Basic Research in Cardiology, 2000, 95, 179-185.	2.5	43